BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024 [Yahoo! Finance]
BeiGene, Ltd. - American Depositary Shares (BGNE)
Last beigene, ltd. - american depositary shares earnings: 3/2 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.beigene.com/phoenix.zhtml?c=254246&p=irol-irhome_pf
Company Research
Source: Yahoo! Finance
Two oral presentations showcase promising safety and efficacy data for BTK chimeric degradation activation compound (CDAC), BGB-16673 Oral presentation highlights continued deep and durable responses and manageable tolerability observed in Phase 1 study of BCL2 inhibitor, sonrotoclax, in combination with BRUKINSA for patients with treatment-naïve CLL/SLL SAN MATEO, Calif., November 05, 2024 BUSINESS WIRE )--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data across a range of B-cell malignancies and assets, including best-in-class Bruton's tyrosine kinase (BTK) inhibitor BRUKINSA ® (zanubrutinib), at the 66 th ASH Annual Meeting and Exposition in San Diego, December 7-10. BeiGene has 21 abstracts accepted at ASH 2024, with four selected for oral presentation. "In the five years since its initial approval, BRUKINSA has become a standard of care for patients facing many B-cell malignancies, and our data feature
Show less
Read more
Impact Snapshot
Event Time:
BGNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BGNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BGNE alerts
High impacting BeiGene, Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BGNE
News
- BeiGene Announces Third Quarter 2024 Financial Results and Corporate UpdatesBusiness Wire
- BeiGene to Present at the Jefferies London Healthcare ConferenceBusiness Wire
- BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024Business Wire
- BeiGene Mourns Death of Beloved Board Member Donald GlazerBusiness Wire
- BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at JPMorgan Chase & Co. from $200.00 to $235.00. They now have an "overweight" rating on the stock.MarketBeat
BGNE
Earnings
- 11/12/24 - Miss
BGNE
Sec Filings
- 11/12/24 - Form 10-Q
- 11/12/24 - Form 8-K
- 10/28/24 - Form 8-K
- BGNE's page on the SEC website